DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

ABBV·AbbVie Inc.

$.
-. (-.%)
Pre-Market
High
$226.35
Open
$225.80
Market Cap
401.47B
52W High
$244.81
Low
$225.50
P. Close
$226.60
P/E
110.45
52W Low
$181.73
Fwd P/E
60.14
DailyIQ Est.
$296.75
Technical Score (1D)
82
BUY
News Sentiment
78
BULLISH
AbbVie has been identified as one of the most underrated dividend‑growth stocks in the S&P 500, a view that has recently gained traction among analysts. The company’s spin‑off from Abbott Laboratories has helped it preserve a legacy of dividend stability, with quarterly payouts climbing from $0.40 to $1.73 per share since 2013. Current valuation metrics place AbbVie at a discount relative to other high‑yield peers, indicating upside potential for income‑focused investors. This perception shift could attract new inflows over the next 1–10 trading days as investors seek higher yields coupled with growth prospects. AbbVie’s strong cash flow and an active biologics pipeline provide the financial foundation to sustain further dividend increases in the near term. The upcoming earnings release will be a key watch item, as any update on revenue growth or pipeline milestones could confirm or challenge the dividend outlook. Investors should also monitor regulatory developments for its key biologic candidates, as approvals or setbacks could impact cash‑flow projections. The broader high‑yield environment and any changes in interest rates could influence the attractiveness of AbbVie’s dividend relative to fixed‑income alternatives. Finally, the next dividend declaration will signal whether the company is on track to continue its growth trajectory. These factors together suggest that AbbVie’s valuation and dividend profile are poised to influence short‑term trading activity.
Earnings Summary
AbbVie is a global biopharmaceutical company headquartered in North Chicago, Illinois, focused on discovering and delivering innovative medicines across autoimmune, oncology, neuroscience, eye care, hepatitis C, and gastrointestinal therapeutic areas, positioning it within the broader drug manufacturers sector. In the most recent quarter, Q4 2025, AbbVie reported EPS of $2.71 versus an estimate of $2.7053, and revenue of $16.618 billion against an estimate of $16.748 billion, marking a continued beat of analyst expectations; the prior quarter, Q3 2025, saw EPS of $1.86 versus $1.7845 and revenue of $15.776 billion, also beating estimates, while Q1 2026 EPS of $2.65 fell short of the $3.7409 estimate and revenue dropped to $15.002 billion from the $16.804 billion forecast, indicating a deceleration in both earnings and top line growth. Historically, AbbVie has posted a streak of five consecutive quarterly EPS beats from Q4 2024 through Q4 2025, with revenue growth accelerating from $15.102 billion in Q4 2024 to $16.618 billion in Q4 2025, underscoring a robust growth trajectory that has been punctuated by a recent EPS miss in Q1 2026 despite a strong revenue base; this pattern suggests that while the company continues to generate solid sales, margin pressures or cost factors may be emerging. Recent regulatory news highlights FDA approval of Decnupaz for a rare blood cancer and European approvals for AQUIPTA and VENCLYXTO migraine combinations, expanding AbbVie’s oncology and neurology portfolios, and a price target lift by Rothschild & Co Redburn to $284, reflecting renewed analyst confidence in the pipeline and earnings outlook; these developments could materially influence future revenue streams and investor sentiment. Forward‑looking watch points for investors include monitoring Q2 2026 earnings for guidance updates, assessing the commercial impact of the newly approved indications, and tracking the timing and competitive landscape of Humira biosimilar entry and the impending patent cliff, all of which will be key to understanding AbbVie’s near‑term earnings resilience and long‑term valuation prospects.

EPS

EstBeatMiss
$1.49$2.13$2.78$3.42$4.07Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.77 - -
Q1'26$3.74$2.65-29.2%
Q4'25$2.71$2.71+0.2%
Q3'25$1.78$1.86+4.2%
Q2'25$2.91$2.97+2.1%
Q1'25$2.40$2.46+2.6%

Revenue

EstBeatMiss
$12.8B$14.0B$15.2B$16.4B$17.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$17.1B - -
Q1'26$16.8B$15.0B-10.7%
Q4'25$16.7B$16.6B-0.8%
Q3'25 - $15.8B -
Q2'25 - $15.4B -
Q1'25 - $13.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABBV Stock Snapshot

ABBV is currently trading at $225.50, giving AbbVie Inc. a market cap of 401.47B and a P/E ratio of 110.5. Today's range spans $225.50–$226.35, with shares opening at $225.80 and moving down $1.10 (0.5%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 78/100.

Over the past year ABBV has traded between $181.73 and $244.81 - the current price is +24.1% off the 52-week low and -7.9% from the high. 42 analysts cover the stock with a Buy consensus and a mean 12-month target of $253.55 (range $184.00–$328.00), implying upside of +12.4%.

Cross-asset context supports the bullish read on ABBV: when Healthcare sector conditions are favorable, large-cap names with 82/100 technical scores (BUY) and bullish sentiment (78/100) outperform on a risk-adjusted basis. Price: $225.50 (in the upper portion of its 52-week range). (P/E: 110.5) The 52-week context of $181.73–$244.81 shows the full trading history - and the current setup is one of the stronger entries within that range. At 401.47B in market cap, position sizing is the key variable, not the direction.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (78/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $225.50 (in the upper portion of its 52-week range), ABBV's position within the $181.73–$244.81 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.